Table 4.
Mean biological effective dose (BED) and tumor control probability (TCP) of the lymph nodes in the three patients with different fractionation schedules. Mean values ± standard deviation
| Patient I | Patient II | Patient III | ||||
|---|---|---|---|---|---|---|
| Schedule | BED (Gy) | TCP (%) | BED (Gy) | TCP (%) | BED (Gy) | TCP (%) |
| 50 Gy/25 Fx | 55.3 ± 25.2 | 44.6 ± 31.4 | 64.8 ± 17.8 | 57.5 ± 22.9 | 12.1 ± 19.2 | 4.4 ± 14.4 |
| 42.5 Gy/16 Fx | 51.8 ± 24.0* | 38.5 ± 28.5* | 60.8 ± 17.0* | 49.9 ± 21.0* | 11.0 ± 17.9* | 3.5 ± 12.1* |
| 40 Gy/15 Fx | 48.9 ± 22.6* | 32.9 ± 25.1* | 57.5 ± 16.1* | 42.5 ± 18.6* | 10.4 ± 16.9* | 2.8 ± 10.1* |
| 27 Gy/5 Fx | 45.6 ± 22.0* | 27.2 ± 22.0* | 54.0 ± 15.7* | 34.9 ± 16.6* | 9.0 ± 15.6* | 2.0 ± 8.1* |
| 26 Gy/5 Fx | 43.1 ± 20.7* | 21.7 ± 18.0* | 50.9 ± 14.8* | 27.6 ± 13.7* | 8.5 ± 14.7* | 1.5 ± 6.4* |
Fx fraction, BED biological effective dose, TCP tumor control probability, Gy Gray
*significant difference compared to the standard fractionation schedule (p < 0.001)